Nucleome Informatics Launches DrSeq IRD Test for Comprehensive Genetic Diagnosis of Inherited Retinal Diseases (IRDs)

▴ Nucleome Informatics
The company extends its gratitude to the Technology Development Board, DST, Government of India, LV Prasad Eye Institute, and Korean counterparts for their support in making this project a reality.
New Delhi, September 09,2024 :
Nucleome Informatics, a leading genomics services provider, is proud to announce the launch of its DrSeq IRD panel, a revolutionary genetic test for diagnosing Inherited Retinal Diseases (IRDs). This test is among the most comprehensive available globally, designed to improve early detection and disease management, especially in individuals with a family history of blindness. IRDs represent a genetically diverse spectrum of disorders that affect the retina, leading to vision impairment or blindness.
In India, the prevalence of IRDs ranges from 1 in 350 to 1 in 2000, varying by region and factors such as consanguinity. Accurate diagnosis of these conditions has been challenging due to their clinical and genetic heterogeneity, with over 300 genes associated with IRDs. However, most cases are caused by mutations in 20 key genes. Nucleome’s DrSeq IRD panel covers an extensive range of IRDs, including:  
● Leber Congenital Amaurosis (LCA)
● Cone Dystrophy
● Cone Rod Dystrophy
● Retinitis Pigmentosa (RP)
● Stargardt's Disease
● Maclaren Dystrophy
● Congenital Stationary Blindness
● Vitelliform Macular Dystrophy
● Bardet-Biedl Syndrome
● Usher Syndrome
● Choroideremia
● Achromatopsia
● Bestrophinopathy

The DrSeq IRD panel includes 850 genes and thousands of known and novel variants, providing superior diagnostic accuracy. The test helps identify the genetic mutations responsible for specific IRD types, which is critical for tailoring treatment options, including gene therapy. The significance of genetic testing is growing as gene therapies advance. These tests enable patients to qualify for clinical trials or access targeted treatments tailored to their genetic profiles.  

In collaboration with LV Prasad Eye Institute (LVPEI), DST (Department of Science and Technology) of the Government of India and Korean partners, including Seoul Eye Hospital, Nucleome Informatics has developed the DrSeq IRD panel by sequencing 300 IRD patients and 200 healthy family members from India. A similar study was conducted using Korean patient samples, further validating the panel’s efficacy across populations. One of the unique aspects of the DrSeq IRD panel is its saliva-based collection method, which eliminates the need for blood samples. Patients can easily provide samples from the comfort of their homes using a saliva collection kit, which will be analyzed at Nucleome's state-of-the-art laboratory in Hyderabad.  

Mr. Dushyant Singh Baghel, CEO of Nucleome Informatics, announced the launch of this innovative test during his participation in a conference at Stanford University, San Francisco. Mr. Baghel expressed his excitement about making the test available in India and shortly globally. He said, “The DrSeq IRD panel marks a significant step forward in tackling the challenges posed by Inherited Retinal Diseases. With this test, we aim to enhance early detection, improve treatment options, and support gene therapy initiatives worldwide. Nucleome Informatics is actively seeking distribution partners globally, as well as gene therapy companies that are targeting IRDs such as Leber Congenital Amaurosis, Stargardt’s Disease, Retinitis Pigmentosa, and other conditions covered by the DrSeq IRD panel”.  

The company extends its gratitude to the Technology Development Board, DST, Government of India, LV Prasad Eye Institute, and Korean counterparts for their support in making this project a reality.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Kaya Expands in Ludhiana with its 76th Clinic, Elevating Skincare with Advanced Wellness Solutions October 09, 2024
Dr Raj Nagarkar Becomes India’s 1st Oncologist on Cambridge Medical Robotics’ Advisory BoardOctober 09, 2024
Workplace Stress and Burnout Rate Reaching Critical Levels for Indian Employees, Warn ExpertsOctober 09, 2024
Are We Really Living Longer? The Surprising Reality of Life Expectancy TodayOctober 09, 2024
Could Your Irregular Heartbeat Be Reversible? How New Research is Redefining Atrial Fibrillation CareOctober 09, 2024
Defying the Odds: The Innovative Treatment Prolonging Life in Advanced Breast CancerOctober 09, 2024
Medanta Doctors Recognised in Stanford University's Global Rankings of Top 2% ScientistsOctober 09, 2024
Vector-Borne Diseases in India: 2024 OverviewOctober 09, 2024
What Makes The Mind Hear Voices: The Truth Behind Hearing Voices in SchizophreniaOctober 08, 2024
Preventing Pregnancy Complications: Why a Healthy Weight Before Conception MattersOctober 08, 2024
Are Your Favorite Beverages Putting You at Risk of Stroke? Here’s What the Latest Research SaysOctober 08, 2024
Sharp Sight Eye Hospitals Emphasizes Importance of Regular Eye Checkups with New Campaign Featuring Shishir SharmaOctober 08, 2024
Microplastics in Bloodstream: The Hidden Link to Cardiovascular and Neurological DisordersOctober 08, 2024
India Joins International Medical Device Regulators Forum: A Leap Toward Global Health CollaborationOctober 05, 2024
The Science of Overeating: Why You Can’t Stop at Just One BiteOctober 05, 2024
The Toxic Truth: How Alcohol Fuels Six Deadly CancersOctober 05, 2024
Lenacapavir: India’s Pharmaceutical Giants to Produce a Twice-a-Year Pill Poised to Rewrite HIV PreventionOctober 04, 2024
Can Ending Smoking by 2050 Really Save 1.2 Million Lives? New Lancet Study RevealsOctober 04, 2024
Colon Cancer Crisis: Why It’s Attacking Younger GenerationsOctober 04, 2024
Eye Health Program for Low-Income Residents Launched in Hingoli, MaharashtraOctober 04, 2024